Antifungal susceptibility testing: Technical advances and potential clinical applications

Clinical Infectious Diseases

Volumn 24, Issue 5, 1997, Pages 776-784

  Pfaller, M A ^a   Rex, J H ^b   Rinaldi, M G ^b  

^a UNIVERSITY OF IOWA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGAR GEL DIFFUSION; CANDIDIASIS; CLINICAL LABORATORY; CLINICAL TRIAL; COLORIMETRY; CRYPTOCOCCOSIS; DILUTION; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SPECTROPHOTOMETRY; TECHNOLOGY; TREATMENT OUTCOME;

EID: 0030938928     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/24.5.776     Document Type: Review

References (18)

1. McCabe WR, Treadwell TL. In vitro susceptibility tests: correlations between sensitivity testing and clinical outcome in infected patients. In: Lorian V, ed. Antibiotics in laboratory medicine. 2nd ed. Baltimore: Williams & Wilkins, 1985:925-37.
2. Murray PR. Antimicrobial susceptibility tests: testing methods and interpretive problems. In: Poupard JA, Walsh LR, Kleger B, eds. Antimicrobial susceptibility testing: critical issues for the 90s. New York: Plenum Press, 1994:15-25.
3. Stratton CW IV. In vitro testing: correlations between bactericidal susceptibility, body fluid levels, and effectiveness of antibacterial therapy. In: Lorian V, ed. Antibiotics in laboratory medicine. 3rd ed. Baltimore: Williams & Wilkins, 1991:847-79.
4. Fisher-Hoch SP, Hutwagner L. Opportunistic candidiasis: an epidemic of the 1980s. Clin Infect Dis 1995;21:897-904.
5. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995;20:1526-30.
6. Pfaller M, Wenzel R. Impact of the changing epidemiology of fungal infections in the 1990s. Eur J Clin Microbiol Infect Dis 1992;11: 287-91.
7. Espinel-Ingroff A, Pfaller MA. Antifungal agents and susceptibility testing. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. 6th ed. Washington, DC: American Society for Microbiology, 1995:1405-14.
8. Ghannoum MA, Rex JH, Galgiani JN. Susceptibility testing of fungi: current status of the correlation of in vitro data with clinical outcome. J Clin Microbiol 1996;34:489-95.
9. Gould IM. Laboratory directed antifungal chemotherapy: controversy or progress? Antiinfect Drugs Chemother 1995;13:59-62.
10. Johnson EM, Wamock DW. Azole drug resistance in yeasts. J Antimicrob Chemother 1995;36:751-5.
11. Ng TTC, Denning DW. Fluconazole resistance in Candida in patients with AIDS - a therapeutic approach. J Infect 1993;26:117-25.
12. Rex JH, Pfaller MA, Rinaldi MG, Polak A, Galgiani JN. Antifungal susceptibility testing. Clin Microbiol Rev 1993;6:367-81.
13. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1-8.
14. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997;24:235-47.
15. Cormican MG, Pfaller MA. Standardization of antifungal susceptibility testing. J Antimicrob Chemother 1996;38:561-78.
16. Espinel-Ingroff A, Kerkering TM, Goldston PR, Shadomy S. Comparison study of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol 1991;29:1089-94.
17. Espinel-Ingroff A, Kish CW, Kerkering TM, et al. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol 1992;30:3138-45.
18. Fromtling RA, Galgiani JN, Pfaller MA, et al. Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. Antimicrob Agents Chemother 1993;37:39-45.